BioNTech (NASDAQ: BNTX) recently raised guidance for the number of doses of its coronavirus vaccine that the biotech thinks it'll be able to produce this year. In this video from Motley Fool Live, recorded on April 5, Fool.com contributors Brian Orelli and Keith Speights discuss whether the increase will actually help the German drugmaker. Unfortunately, between a supply glut and the inability for developing companies to pay full price, the added capacity may not help BioNTech's bottom line that much.
Associate Faculty Director at the Harvard Global Health Institute Dr. Ingrid Katz joined Yahoo Finance Live to break down the latest news on vaccines as Pfizer and Biontech seek full FDA approval
Dr. Gustavo Ferrer, President of Aventura Pulmonary Institute, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus pandemic.